Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
14 nov. 2023 07h00 HE
|
Femasys Inc.
- 510(k) product clearance gained for lead product, FemaSeed potentially allowing sooner-than-expected product commercialization - - Patient enrollment has commenced in landmark, pivotal FINALE...
Femasys Inc. EU MDR Final Audit Successfully Completed
26 oct. 2023 08h30 HE
|
Femasys Inc.
– Completion of the European Union Medical Device Regulation (MDR) final audit is the last step in obtaining an MDR certificate and CE marking, confirming Femasys’ compliance with the highest required...
Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons
25 oct. 2023 08h00 HE
|
Femasys Inc.
ATLANTA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office,...
Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
11 oct. 2023 07h00 HE
|
Femasys Inc.
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (Nasdaq: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office,...
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
04 oct. 2023 08h30 HE
|
Femasys Inc.
ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office,...
Femasys Inc. MDSAP Surveillance Audit Successfully Completed
03 oct. 2023 08h30 HE
|
Femasys Inc.
– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed to bringing innovative solutions to women around...
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate
27 sept. 2023 08h00 HE
|
Femasys Inc.
The first academic center activated to enroll, led by an instrumental investigator who participated in Femasys’ earlier FemBloc studies -FemBloc is being developed as a first-of-its-kind, non-surgical...
Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
25 sept. 2023 17h25 HE
|
Femasys Inc.
- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed®, an intratubal artificial insemination option designed to augment...
Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control
20 sept. 2023 08h30 HE
|
Femasys Inc.
ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office,...
Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 08h30 HE
|
Femasys Inc.
ATLANTA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with two lead revolutionary product...